The Present Condition of Sickle Cell Disease: An Overview of Stem Cell Transplantation as a Cure
Pharmaceutical Fronts, ISSN: 2628-5096, Vol: 5, Issue: 2, Page: E57-E63
2023
- 1Citations
- 6Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Most Recent News
Jaipur National University Researcher Highlights Recent Research in Gene Therapy (The Present Condition of Sickle Cell Disease: An Overview of Stem Cell Transplantation as a Cure)
2023 JUN 12 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Daily News -- Investigators publish new report on gene therapy. According
Article Description
Treatment of sickle cell disease (SCD) remains largely palliative. While it can enhance living standards, persons having SCD still suffer from extreme sickling crises, end-organ destruction, and reduced life expectancy. Increasing research has resulted in the recognition and advancement of stem cell transplantation and gene therapy as possible solutions for SCDs. However, there have been various factors that have hindered their clinical application. The more advantageous of the two, stem cell transplantation, is constrained by a small donor pool, transplant difficulties, and eligibility requirements. The current article reviewed the literature on SCDs, current treatment options, and more particularly the progress of stem cell transplants. It outlined various challenges of stem cell transplant and proposed ways to increase the donor pool using alternative strategies and modifications of regimen conditioning with minimal transplant-related toxicities and associated complications.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85199497625&origin=inward; http://dx.doi.org/10.1055/s-0043-1768918; http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-1768918; https://dx.doi.org/10.1055/s-0043-1768918; https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0043-1768918
Georg Thieme Verlag KG
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know